Recent update on discovery and development of Hsp90 inhibitors as senolytic agents

Area of Science:

• Molecular Biology
• Oncology
• Gerontology

Background:

• Heat shock protein 90 (Hsp90) is a key molecular chaperone targeted for cancer therapy.
• Hsp90 inhibitors have faced challenges in cancer treatment due to toxicity and development costs.
• Emerging research highlights the senolytic potential of Hsp90 inhibitors beyond cancer applications.

Purpose of the Study:

• To review Hsp90 inhibitors investigated as senolytic agents.
• To discuss the future prospects of Hsp90 inhibitors in senolytic therapy.
• To explore models used for evaluating senolytic effects.

Main Methods:

• Literature review of Hsp90 inhibitors.
• Analysis of senolytic properties and therapeutic potential.
• Examination of preclinical models for senolytic evaluation.

Main Results:

• Hsp90 inhibitors exhibit a promising senolytic effect, clearing senescent cells.
• This senolytic activity has demonstrated benefits in increasing healthspan and lifespan in mice.
• Senolytic properties may lead to reduced toxicity compared to traditional Hsp90 inhibitors.

Conclusions:

• Hsp90 inhibitors represent a novel class of senolytic agents with potential therapeutic applications.
• Their senolytic effect offers a promising avenue for treating age-related diseases and potentially improving cancer therapy outcomes.
• Further research into Hsp90 inhibitors as senolytics is warranted, alongside the development of appropriate evaluation models.